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Abstract
Aim Rising concern for demonstrated real world comparative
effectiveness has heightened interest in “pragmatic trials”
design. Pragmatic trials investigate whether the efficacy, pre-
sumed or found in explanatory trials under ideal conditions,
can also be detected under real world conditions, i.e. effec-
tiveness. It is also recognized that ‘real world’ effects which
are usually addressed in public health research gain growing
interest in confirming the ‘road capability’ of results obtained
under ideal study conditions. This paper demonstrates that
studies under ideal or real world conditions use different
methods, generate different information and cannot replace
each other.
Subjects and methods The PCT design meets four require-
ments of public health and of effectiveness research. It
includes all individuals who presented with the selected
condition. It classifies the included individuals according
to baseline risks. It enables plausibility controls. Finally, it
compares the outcomes resulting from specified and not-
specified interventions or treatments.
Proposal We propose a pragmatic controlled trial (PCT)
design in which patient preference and other co-factors
crucial in determining the actual effectiveness of interven-
tional options will not be neutralized by concealed random-
ization and blinding. This design is applicable to record the
selected interventions and generated outcomes in day-to-day
health care and is capable of incorporating preference and
other participative factors into assessment of effectiveness.
Conclusions The PCT design is useful for public health re-
search, e.g. the effectiveness of interventions to change smok-
ing habits or to prevent death from breast cancer, as well as for
comparative effectiveness research where it will supplement
the traditional randomized controlled trial (RCT).
Keywords Randomized controlled trial (RCT) . Pragmatic
controlled trial (PCT) . Public health research . Comparative
effectiveness research . Internal validity . External validity
Background
Randomized controlled trials (RCTs) are frequently consid-
ered the gold standard of clinical research and superior to non-
randomized trials. Accordingly, strictness of randomization,
concealment of allocation and extent of blinding are consid-
ered to constitute the principles of the quality of clinical trials
(Jadad et al. 1996). This position may be problematic if a RCT
is not the optimal method to answer a certain research ques-
tion. In this case, researchers are prevented from deliberately
and carefully selecting the specific optimal study design and
therefore violate an important principle of scientific research,
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i.e. the coherence of trial design and study purpose, which is
well established within the methodological literature (Spilker
1991).
Discussions of the relative merits of ‘explanatory’ and
‘pragmatic’ trials, a distinction introduced by Schwartz and
Lellouch (1967), frequently revolve around issues of similar-
ity of research to real world conditions with respect to patients,
interventions, comparisons and outcomes (Karanicolas et al.
2009; Oxman et al. 2007) However, Schwartz and Lellouch
(1967) emphasized that the two types of trial correspond to
two distinct objectives, with ‘explanatory’—ideally a RCT—
trials seeking answers to the question of whether an interven-
tion “can work”, in contrast to ‘pragmatic’ trials seeking
answers to the question of whether the intervention “does
work” in the context of actual clinical practice. In a recent
published exchange of ideas, one commentator suggested that
Schwartz and Lellouch’s concept be abandoned in favour of a
distinction between trials that investigate the biological mech-
anism and trials that aim for practical application (Karanicolas
et al. 2009). This proposal was criticized as obscuring
Schwartz and Lellouch’s differentiation between the objec-
tives of different categories of a clinical trial, all of which
focus on clinical outcomes related to interventions (Oxman et
al. 2009).
The aforementioned proposals and controversies have
been confined to contrasting visions of research objectives
and the practical application of randomized trials. They have
not considered aspects of a pragmatic trial design and objec-
tives that are incompatible with randomization and blinding.
As pointed out by Oxman et al. (2009), the issues in these
debates are largely reducible to matters of applicability of
randomized trials to practice and policy decisions. For ex-
ample, the nature and extent of patient selection, the inten-
sity of monitoring and the level of compliance of both
patients and practitioners with the study protocol, including
compliance with medications, may be a matter of degree.
Indeed, the discussions are pervaded by the notion that the
distinction between explanatory and pragmatic defines a
continuous spectrum (Thorpe et al. 2009; Sackett 2006).
Thorpe et al. (2009) propose a rating tool for the purpose
of locating a particular trial or design on such a spectrum.
Clinical researchers have recognized that RCTs are not
sufficient to answer all important questions (Schwartz and
Lellouch 1967; Karanicolas et al. 2009; Oxman et al. 2007).
Public health researchers have recently emphasized that
adequate alternatives to RCTs are needed in public health
research (Bonell et al. 2011; Cousens et al. 2011). Clinical
research is usually testing a hypothesis, e.g. comparing two
treatments by designing an ideal experiment, e.g. a con-
cealed and blinded randomized trial. By using this approach,
effects can be excluded which are considered as confound-
ers such as doctor and patient expectations, preferences and
placebo effects. Public health research usually analyzes
observed coincidences and investigates a possible causal
relationship. This research does not exclude doctor and
patient expectations, preferences and placebo effects. New
approaches therefore propose advanced statistical methods
to identify and explain the variance in non-randomized trials
(Cousens et al. 2011; Porzsolt et al. 2012). Explanatory
trials can demonstrate efficacy, i.e. whether a principle
would work under ideal conditions, but it cannot demon-
strate effectiveness, i.e. whether the same principle would
also work under real world conditions. This second effect
can only be detected in pragmatic trials.
Two examples demonstrate that this conflict of results
obtained under ideal versus real world conditions is a current
topic in medical research—the efficacy of nicotine replace-
ment therapy had been confirmed some years ago in a
Cochrane review-based on randomized trials (Stead et al.
2008), while the opposite effect was found in a cohort study
describing the effectiveness of such interventions (Alpert et al.
2012). A comparable conflict is ongoing in breast cancer
screening. Recent articles usually based on cleverly designed
pragmatic trials (Zahl et al. 2008; Zahl et al. 2011) express
considerable doubts on the value of breast cancer screening.
The details behind explanatory and pragmatic trial designs are
addressed in the present paper.
Pragmatic controlled trials (PCTs) consider
expectations, preferences and ‘placebo effects’
The aforementioned discussions are pertinent to the issue of
the applicability of conclusions drawn from randomized
trials to healthcare decisions made under practical condi-
tions. However, they do not address the broader issue of
when randomization and blinding do, and do not, reflect a
study design appropriate to the objectives of pragmatic
trials. Specifically, the roles of patient expectation, patient
preference and the so-called placebo effect may in many
situations play a decisive role in determining the effective-
ness of an intervention aimed at improving patient outcomes
in actual care settings. Treatment preferences of doctors,
nurses and patients are different and are likely to have
different impact on the final treatment decisions. Such pref-
erences can in fact be measured by methods such as conjoint
analysis, but require complex and intensive studies (Porzsolt
et al. 2010a). Such studies are common in market research
but are rarely completed in health care research. Even if the
reported preferences in mind can be identified in preference
studies, one cannot exclude that the communicated theoret-
ical preferences will be identical to the options that have to
be selected under real conditions. More important than the
identification of the hypothetical preferences of patients,
doctors and nurses might be the option that will finally be
selected. Hence, research with the objective of illuminating
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the practical effectiveness of such interventions must choose
a design that incorporates these ‘co-factors’. In such situa-
tions, randomization and blinding must yield to an alternative
design.
Waber et al. (2008) elegantly demonstrated the potential
role of patient expectation in determining outcomes by
using 82 medical students as subjects. The students were
informed that they would receive different pain-killers to
control pain in their feet induced by electrical strikes. The
probands, in fact, received the same placebo but reported
different degrees of pain relief depending upon the type of
information provided. This experiment demonstrated that
expectations induced by information might influence the
comparative effectiveness of a pain treatment. However, this
experiment cannot be replicated among patients for ethical
reasons. More broadly, Brewin and Bradley (1989) compel-
lingly described the circumstances under which patient pref-
erences are inherently bound to potential effectiveness. In
particular, in the case of counselling interventions, and other
interventions requiring active participation of the patient, it
is well established that patient preference and willingness
constitute an inherently necessary condition for effective-
ness (Brewin and Bradley 1989). Hence, a design random-
izing patients to a treatment mode, irrespective of their
preferences, could not, by definition, yield results relevant
to real world effectiveness. Finally, Kaptchuk et al. (2008),
in a three-arm randomized trial, demonstrated a ‘dose-re-
sponse’ effect on quality of life outcomes of what otherwise
might be called the ‘placebo’ effect. While their design did
not directly address patient or practitioner preferences, their
observations suggest that anticipation, expectation and clin-
ical interaction constitute strong determinants of real world
effectiveness, i.e., the bonding of preference between prac-
titioner and patient for a treatment may well influence the
magnitude of the ‘placebo’ effect achieved in association
with a treatment choice.
Practitioners and patients with strong preferences may
refuse participation in a randomized trial and consequently
will increase the risk of sampling bias. Patients with weak
preferences will increase the risk of performance bias as
those who receive their preferred treatment will more benefit
from treatment than those who will get the not-preferred
treatment. Figure 1 illustrates that these ‘preference-based
effects’ can only be avoided if either the same proportions of
patients prefer one of the choices or the treatments can
successfully be blinded. It is interesting that systematic
reviews which explicitly searched for ‘preference-based
effects’ could not confirm the postulated results (Stengel et
al. 2006; King et al. 2005). This is likely attributable to the
fact that most preference-based trials have conformed to a
design in which allocation by preference follows initial
acceptance or rejection of randomization (Stengel et al
2006; Porzsolt and Stengel 2006). Hence, patients with a
strong preference for one of the therapeutic options were
likely to reject randomization, thereby masking the prefer-
ence effect across the study arms. These experiments con-
firm that it is rather difficult to quantify ‘preference-based
effects’.
In summary, the conventional design of trials utilizing
randomization, concealment of allocation and blinding to
treatment arm with the objective to test efficacy of interven-
tions is likely to fail to accurately assess real world effec-
tiveness due its inability to capture the multiple mechanisms
contributing to clinical outcomes. Although such trials may
incorporate some features of a pragmatic or ‘real world’
orientation, such as broad patient selection, laxity on com-
pliance controls and intensity of monitoring, preference-
based effects will be distorted or obscured. Although shared
preference for therapeutic options will generally increase the
real world effectiveness, other practical issues such as co-
morbidity, patient and practitioner compliance may decrease
it. Accordingly, a trial design is required which is capable of
capturing most real-world issues, including preference-
based effects, in order to fully assess effectiveness. We here
describe the outline of three-arm non-randomized pragmatic
controlled-trial design.
Proposal for a pragmatic controlled trial design
The proposed study design, appropriate for demonstration
of the effectiveness, is shown in Fig.2 and is named prag-
matic controlled trial (PCT). In a PCT, data of all patients of
the total service population are included in the evaluation.
The suitability of this step has eventually been approved by
an institutional review board. By inclusion of all patients,
the risk of selection bias is reduced. The administered treat-
ment will not randomly be selected but will be based on
80% of the population prefer treatment A




















Fig. 1 The randomization will generate different groups of patients
unless the patients’ preferences are equally distributed, i.e. 50:50, in the
randomized population. If distributed unequally, as described in the
example, rather huge differences may occur in the proportions of patients
who receive the preferred treatment option
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existing preferences of doctors and patients. To maintain
some control over the effect of different baseline risks on
outcome, the patients are allocated to high, intermediate,
and low risk groups respectively, using the best prognostic
criteria available such as validated prediction rules. The
selection of prognostic criteria will depend on the investi-
gated outcome, i.e., the assessment of different outcomes
requires consideration of different prognostic criteria.
Different treatments are then compared within identical risk
strata (horizontal comparison in Fig. 2). An important ad-
vantage of the design is that the accuracy of the selected risk
criteria can be verified by comparing the vertical groups in
Fig. 2. Low risk patients and high risk patients who receive
the same treatments should demonstrate different outcomes.
The first two of the three study arms of the PCT investi-
gate the clinical outcomes of two favored treatment options
applied under day-to-day conditions. This means that the
selection of the treatment should be based on the informa-
tion ideally derived from explanatory trials and on the
doctors and patients preferences. The third study arm in a
pragmatic trial has to guarantee that the outcomes of all
treated patients are reported in order to reduce the risk of
selection bias. Therefore, the third study arm should include
all eligible patients who were seen in the participating
institution during the study period except those patients
who are reported in one of the first two study arms. This
inclusion criterion represents an important difference be-
tween explanatory and pragmatic trials.
If the pragmatic controlled trial fails to confirm a differ-
ence between the two investigated treatments (A and B in
Fig. 2), the results of the two investigated treatments should
be compared with the third study arm. This additional step is
necessary to test the specificity of the result. It has to be
demonstrated that these two treatments—despite of similar
effectiveness—generate better outcomes than the average of
any other treatments (in the mixed third group).
The similarities and differences between the three-arm
PCT design we are proposing and the conventional random-
ized explanatory trial are highlighted in Table 1. Six of the
ten steps (step Nos. 1, 2, 3, 7, 8 and 10) are identical in
explanatory and pragmatic trials. The remaining four steps
(step Nos. 4, 5, 6 and 9) are similar. However, it is worth
mentioning that the sequence of step Nos. 4–6 differs be-
tween explanatory and pragmatic trials. These ten steps
guide to implement the appropriate study design (Porzsolt
et al. 2010b).
Discussion
The research design described in this paper is based on the
concept “Form Follows Function” that was developed as a
guide for the construction of the first skyscrapers in Chicago
(Sullivan 1896). This concept is applied to two types of
research, explanatory and pragmatic trials to different research
areas, clinical research and public health research and to
different clinical trials which intend to measure two outcomes
under two different conditions. According to the Framework
for Design and Evaluation of Complex Interventions to
Improve Health published by the UK Medical Research
Council (Campbell et al. 2000), a clinical trial can only be
effectively implemented if the problem to be solved has been
properly addressed. Despite the persistent problem concerning
an exact definition of the essential characteristics of a clinical
trial (Wright et al. 2008), we can conclude that the quality of a



















Total populationFig. 2 Differences of
randomized controlled trials
(RCT) and pragmatic controlled
trials (PCT). It is shown that a
particular total population of
patients (e.g. in a hospital or
clinic) will include patients with
high risk (black), intermediate
(gray) and low risks (white) for
a condition that should be
prevented by the selected
treatments (e.g. hospitalization
of more than two weeks or
death). A detailed description of
the differences between RCTs
and PCTs is given in the text
310 J Public Health (2013) 21:307–313
question is not absolutely clear. The two basic categories of
questions that are asked in clinical medicine are:
– “Does a new principle work at all under ideal study
conditions, i.e. is it efficacious”?
– “Will the efficacious principle do under real world con-
ditions what it promised to do under ideal study con-
ditions, i.e. is it effective ”?
Consequently, explanatory trials measure efficacy under
ideal but artificial conditions, while pragmatic trials measure
effectiveness under real day-to-day conditions. For clarity
reasons, we do not consider any other, e.g., mixed condi-
tions. When extracting the essential steps of experimental
and pragmatic trials, one will essentially end up with the
steps described in Table 1 and Fig. 2, which illustrate several
important differences.
The pragmatic trial design is particularly pertinent in the
investigation of effectiveness of interventions affecting pub-
lic health. Screening interventions and interventions to mod-
ify individual susceptibility to disease are subject to public
debate and controversy and therefore likely to be associated
with strong patient and practitioner preferences, which in
turn may affect outcome. A notable example is that of breast
cancer screening. Recent recommendations against routine
screening for women under age 40 on the part of an inde-
pendent guideline group in the United States were met by
divisive and polarized debate and corresponding coverage in
the popular press (Quanstrum and Hayward 2010).
The efficacy assessed in an explanatory trial must not be
misinterpreted as a pure effect mediated by a specific treatment.
Like effectiveness, efficacy is a mixed effect caused by a spe-
cific intervention and by confounders. The difference between
efficacy and effectiveness is that the confounders in experimen-
tal and control groups are (ideally) identical in an explanatory
trial but may be different in a pragmatic trial. By definition of the
inclusion and exclusion criteria, the number of confounders is
reduced in an explanatory trial in contrast to a pragmatic trial in
which the access is not limited by these criteria. Testing the
external validity of an effect—presuming that the internal valid-
ity is known—requires several pragmatic trials as a large num-
ber of conditional and environmental factors has to be controlled
(Di Blasi et al. 2001). The randomization in explanatory trials is
replaced by stratification according to risk groups in pragmatic
trials. Finally, the intent-to-treat analysis in explanatory trials is
replaced by Bayesian statistics in pragmatic trials. This means
that patients should be evaluated in the treatment groups to
which they were allocated at the start of treatment even if the
treatment was subsequently changed.
If these simple instructions for the planning and conduct of
clinical trials are followed, the information gained from properly
conducted explanatory and pragmatic trials may be more valu-
able than that derivable from even the best controlled explana-
tory trial. The best information an explanatory trial can provide
is the certainty that efficacy has been demonstrated by valid
methods. From such results it may be expected that the treat-
ment under investigation will work under real-world conditions.
Advantages, limitations and challenges of explanatory
and pragmatic trials
The advantages, limitations and challenges of explanatory
and pragmatic trials can be summarized as follows. The
results of a properly conducted pragmatic trial will provide
Table 1 The recommended steps in explanatory and pragmatic trials
Step Nos. Explanatory trial Pragmatic trial
1 Define the type of research (explanatory or pragmatic trial) that should be completed
2 Phrase the four parts of the precise study question according to the principles of Evidence-Based Medicine
3 Select the most appropriate study design (among explanatory or pragmatic designs)
4 Define inclusion/exclusion criteria and the investigated treatment options Define patient risk groups and the investigated treatment
options
5 Ask eligible patients to sign the informed consent for randomization,
blinding, treatment, evaluation and publication of data
Allocate all patients according to doctors‘ and patients‘
preferences to treatment options or to “other treatment”
6 Randomize the eligible patients who signed the informed consent to the
selected treatment options
Ask all patients to sign the informed consent for
evaluation and publication of the data
7 Assure that the follow up period is long enough to observe a sufficiently large number of study endpoints
8 Demonstrate in ‘Table 1’ the similar distribution of baseline risks within the compared study groups
9 Analyze the results according to the ITT principle Analyze the results according to Bayesian Statistics
10 Use appropriate statistics to confirm non-random effects.
ITT intention-to-treat principle. Neither the topics (colors) nor the sequence of the topics are identical in explanatory and pragmatic trials indicating
that both, content and sequence of the steps are different
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information on the distribution of risks in the investigated
patient groups. This information is not available in usual
randomized trials. The pragmatic trial will also provide
information on the effect of the selected intervention as
compared to others. The interesting aspect is that all patients
are stratified according to their chance to respond favorably
to the investigated treatments or according to their risk of
treatment failure. This means that the effects of treatments
other than those being explicitly investigated serve as con-
trols. An additional important difference between explana-
tory and pragmatic trials is related to the selection of
patients. Patients who are eligible according to the inclusion
criteria but are excluded in order to focus the target group or
patients who refuse one of the investigated treatments, e.g.
due to strong preferences, are not included in explanatory
trials and therefore not considered in the evaluation of the
results. In the pragmatic trials, we propose to include all
eligible patients (i.e. patient who meet the inclusion criteria)
and to evaluate these patients according to their baseline
risks but regardless of preferences or the selected treatments.
The proposed design of non-randomized trials we have
presented here should be interpreted neither to imply that
explanatory, or “efficacy”, trials are irrelevant nor that ran-
domized trials have no proper role in the evaluation of real
world effectiveness. Rather, since they may confirm unique-
ly attributable effects of high cost, resource intensive, inter-
ventions, efficacy trials may be considered as an essential
pre-requisite evidence of benefit by both, policy makers and
practitioners, prior to the commencement of pragmatic tri-
als. In other words, pragmatic trials, precisely because they
demonstrate association with benefit in the real world con-
text of multifactorial determinants of outcome, rather than
specifically attributable effect, are premised on either prov-
en or assumed efficacy of specific interventions being eval-
uated. In other words, in the setting of actual clinical care,
all interventions are, to one extent or another, components of
a ‘care bundle’, and it is the bundle, not the unique inter-
vention, that is being evaluated for effectiveness. The con-
cept of a ‘care bundle’ leads to the question on how many
PCTs will be necessary to cover all important treatment
modification that can definitely not be covered by specific
RCTs. The answer may be that any treatment modification
that is expected to generate better outcomes than an estab-
lished therapy in any dimension (survival, quality of life
including patient safety, monetary costs) should be sup-
ported by results of a PCT. In contrast to RCTs, it will be
much easier to describe the most frequently used variations
of a treatment protocol in a PCT because the sequence of
step Nos. 4–6 (Table 1) of the treatment selection and the
treatment reporting are different in explanatory and pragmatic
trials. There will always be some variation in the adherence to
a particular treatment protocol and it is always a matter of
discussion which deviations can or cannot be tolerated in a
trial. It is recommended in PCTs to describe prospectively the
tolerated deviations from the investigated treatment protocols
as well as the observed deviations from the investigated
treatment options. As a large variation of individual treatment
modifications will be observed, it is recommended to specify
at least the most frequently used treatments in the third
study arm.
The three-arm trial design that we have described is
uniquely suited to contexts subject to tangible mechanisms
of contributory effect of patient preference, what Brewin
and Bradley (1989) refer to as “participative” interventions
in which motivational variables play an inescapable role. In
such settings, randomization and blinding inherently ob-
scure the comparative effectiveness that a formal trial seeks
to establish. In the case of interventions in which the partic-
ipative component is concealed or absent, randomized trials
that seek to address practical concerns may provide useful
information that can guide policy and practice decisions.
Conclusion
A significant step forward in the development of clinical
trials can be taken, if we accept the principle that ‘form
follows function’. This means that the problem to be solved
in a research question is defined, the results are described in
terms of either efficacy or effectiveness (but not as a mixture
of both), and the limited consequences that can be derived
from the obtained results are clear. When accepting the
principle ‘form follows function’ for clinical trials it will
be possible to shorten the development of new treatments
from the bench to usual care and to generate reliable real
world results when expectations, preferences and placebo
effects will be included in the analysis.
A randomized clinical trial is a valuable tool but it can
neither be used to solve any research question nor should it
be regarded any longer as adequate in itself to address two
different and essential types of questions: “Does a new
principle work at all under ideal study conditions, i.e. is it
efficacious” and “will the efficacious principle do under real
world conditions what it promised to do under ideal study
conditions, i.e. is it effective”?
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